DNA damage-inducible transcript 4 protein (DDIT4) (DDIT4)

DNA damage-inducible transcript 4 protein (DDIT4), also known as REDD1 or RTP801, is a highly conserved stress-responsive protein that serves as a critical negative regulator of the mechanistic target of rapamycin complex 1 (mTORC1). It is rapidly induced in response to various cellular stressors, including hypoxia, DNA damage, energy depletion, and oxidative stress, acting as a molecular switch to downregulate cellular growth and protein synthesis. Mechanistically, DDIT4 inhibits mTORC1 by facilitating the assembly and activation of the TSC1/TSC2 complex, which subsequently inactivates the GTPase Rheb. Beyond its role in normal physiology, DDIT4 is implicated in the pathogenesis of several diseases, including various cancers where it often correlates with poor prognosis and therapy resistance, as well as neurodegenerative conditions like Parkinson's and Alzheimer's diseases. Therapeutic interest in DDIT4 has led to the development of siRNA-based inhibitors, such as PF-04523655, which have been evaluated in clinical trials for retinal disorders like diabetic macular edema. Additionally, certain existing drugs like metformin and dexamethasone are known to modulate DDIT4 expression, further highlighting its importance as a therapeutic node. The protein's dual role as both a potential oncogene and tumor suppressor depending on the cellular context presents a significant challenge for drug development. Overall, DDIT4 represents a key link between environmental stress and the control of cellular metabolism and survival.

Other names

REDD1RTP801Dig2Protein regulated in development and DNA damage response 1HIF-1 responsive protein RTP801REDD-1

DDIT4 inhibits the mTORC1 complex by promoting the stabilization and activation of the TSC1/TSC2 complex, which in turn inactivates the GTPase Rheb, a necessary activator of mTORC1.